Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ( “Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

ConclusionPom ‐PAD‐Dara represents a promising multiagent regimen in heavily pretreated RRMM patients with high ORR and an acceptable safety profile.

Source: Cancer Medicine - June 30, 2020 Category: Cancer & Oncology Authors: Xiang Zhou, Maximilian J. Steinhardt, Denise Grathwohl, Katharina Meckel, Katharina Nickel, Hans ‐Benno Leicht, Franziska Krummenast, Hermann Einsele, Leo Rasche, Klaus M. Kortüm Tags: ORIGINAL RESEARCH Source Type: research